“Now that we have clearance from the US Food and Drug Administration, we are ready to move quickly to start introducing the NeoNavia system to clinicians and potential partners in the US,” said Anna Eriksrud, CEO of NeoDynamics. “Teaming up with Diligent to start our sales effort is a key milestone for the company. The US breast biopsy market is expected to reach $830 million by 2025 so this is an exciting moment for the company’s future.”
Diligent will assist NeoDynamics in communicating with patients, caregivers, and health care professionals, from initial consultation to strategic implementation and daily operations. Their specialists will support the company’s efforts to manage medical information, reimbursement and coding services.
“The entire leadership team of Diligent Health Solutions is excited to be supporting NeoDynamics for the US launch of its NeoNavia biopsy system. This innovative, ultrasound-guided system will be of significant value to people facing a breast cancer diagnosis as well as to their health care providers,” said Diligent’s Eva Mitchell, VP of Business Development.
NeoNavia is an innovative biopsy system that uses a patented pulse technology for controlled and accurate needle insertion. It is based on research at the Karolinska Institutet in Stockholm. NeoDynamics’ goal is for the pulse technology to become the new standard for ultrasound-guided breast biopsies. The product has CE approval in Europe, where it is in clinical use.